Wedbush Downgrades Global Blood Therapeutics to Neutral

Wedbush analyst Andreas Argyrides downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Neutral.

Wedbush analyst Andreas Argyrides downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Neutral.

Total
0
Shares
Related Posts